ATLASATLAS fair value
$11.11
Close to fair value · 1% premium
Range: $7–$19Fair valuePrice
ADMA Biologics (ADMA)
ADMA Biologics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$11.17▲ +0.95%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
49%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on ADMA Biologics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On ADMA Biologics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates ADMA Biologics's fair value at about $11.11 per share (reasonable range: $6.52 to $18.94). At $11.17, the stock trades within 8% of that figure: close to fair value.
It is calculated with a blend of a discounted cash-flow model and peer valuation multiples. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives ADMA Biologics a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $10.33 and $12.02; in 9 out of 10, between $9.04 and $13.75. Estimated annual volatility is 39%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $2.2B
- P/E ratio
- 12.9
- 52-week high
- $20.46
- 52-week low
- $7.21
- Revenue (12 months)
- $512M
- Revenue growth (YoY)
- +19.6%
- Earnings growth (YoY)
- -25.9%
- Gross margin
- 57.4%
- Operating margin
- 37.5%
- Net margin
- 28.8%
- Return on equity
- 41.9%
- Free cash flow (12 months)
- $54.8M
- Beta
- 0.77
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. ADMA Biologics sits close to fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks ADMA has traded between $7.21 and $20.46. Today it is 45.4% below that high and 55% above its low.
On the business: revenue grew 19.6% year over year; net margin is 28.8%; it trades at 12.9 times earnings.
Its beta is 0.77: it tends to move less than the market.
About the company
ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing specialty plasma-derived biologics for patients with immune deficiencies and certain infectious diseases.
Want to see everything about ADMA Biologics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is ADMA Biologics (ADMA) fair value?
About $11.11 per share according to ATLAS (reasonable range: $6.52 to $18.94). With the stock at $11.17, it is close to that value.
What is the chance ADMA goes up next month?
49%: close to a coin flip. In half of the simulated outcomes, ADMA ends the month between $10.33 and $12.02.
How big is ADMA Biologics and what is its P/E ratio?
ADMA Biologics's market capitalization is $2.2B. Its price-to-earnings (P/E) ratio is 12.9: you pay $12.9 for each $1 of yearly earnings.
How volatile is ADMA?
ATLAS estimates annual volatility at 39%. In a typical month, half of the outcomes end between $10.33 and $12.02.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer